Feinberg School of Medicine

Chaired by founder Stephen Birrell, MD PhD, group includes experts in breast cancer biology, endocrine signaling and biomarker-driven risk reduction strategies BOULDER, Colo.--(BUSINESS WIRE)--Havah Therapeutics, a clinical stage biopharmaceutical company developing innovative, proprietary hormonal implant therapies for prevention and treatment of breast cancers, announced the formation of their Clinical Advisory Board Chaired by Havah Therapeutics founder Stephen Birrell, MD, PhD. “The scientific and clinical guidance of this esteemed group will be invaluable as we advance our androgen targeted therapy into late-stage clinical studies for Ductal Carcinoma In-Situ (DCIS) and investigator-sponsored combination studies in more advanced disease,” said, Matthew Brewer, CEO of Havah Therapeutics. Shelley Hwang, MD, MPH, Breast Cancer Research Foundation (BCRF) Investigator and internationally recognized expert in pre-invasive disease and DCIS, added: “I am thrilled to be involved with Havah Therapeutics at this critical stage of their development. Insights gained from their ongoing Phase 2 study ( RECAST DCIS ), coupled with my experience as the principal investigator of the COMET Study , will potentially enable the company’s androgen receptor targeting therapy to provide a much needed treatment alternative to invasive surgery and radiation treatment.” The members of Havah Therapeutics’ Clinical Advisory Board include: Stephen Birrell, MD, PhD (Chair), is founder of Havah Therapeutics and Chief Medical Officer of Wellend Health, an Australia-wide clinic that specializes in breast hormone-health, women at high-risk breast cancer and clinical trials. He is a Clinical Affiliate academic at the University of Adelaide Dame Roma Mitchell Cancer Research Laboratories. Shelley Hwang, MD, MPH is the Mary and Deryl Hart Distinguished Professor of Surgical Oncology and Radiology, Vice Chair of Research and Disease Group Leader for the Breast Cancer Program at Duke University Comprehensive Cancer Center. Her research focus includes breast cancer prevention, identifying less invasive treatments for early-stage breast cancers including DCIS and addressing and mitigating health care disparities in breast cancer. Seema A. Khan, MD is Professor of Surgery in the Feinberg School of Medicine at Northwestern University, and the Bluhm Family Professor of Cancer Research. She is the Co-Leader of the Cancer Prevention Research Program at the Robert H. Lurie Comprehensive Cancer Center. Her research focuses on applying biomarker knowledge to improve breast cancer risk stratification and develop preventive interventions for high-risk women. Her research is funded by the National Institutes of Health, The Breast Cancer Research Foundation, the Avon Foundation, and the Susan G. Komen Foundation Professor Wayne Tilley, PhD is the Inaugural Director of the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide. He completed a Fellowship at UT Southwestern in Dallas Texas in the late 1980s where he was one of the first to clone the human androgen receptor (AR) with Professor Jean Wilson, MD. A current major research focus of Professor Tilley’s lab is the development of new treatments for breast cancer that stimulate the tumor suppressive activity of the AR in the breast (Nature Medicine 2021; Lancet Oncology 2024) to counter the proliferative effects of estrogen. Additional background information on the CAB members can be found on the company’s website: About RECAST DCIS Havah Therapeutics is currently participating in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. Havah Therapeutics’ HAVAH T+Ai™, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways, is being evaluated alongside two other endocrine therapy arms. About Havah Therapeutics Havah Therapeutics is developing a novel therapeutic implant for treating hormonally sensitive cancers and other breast conditions. This groundbreaking method relies on stimulating (agonizing) the androgen receptor in breast tissue, utilizing natural hormonal mechanisms to treat patients safely and with greatly reduced side effects. The product is a combination of two registered agents (testosterone and anastrozole, a low dose aromatase inhibitor) that when dosed, provides three months of continuous medication enabling a superior product pro compliance, safety and efficacy. For more information, visit . Contacts Media Contacts: Matthew Brewer mb@havahtx.com Danielle Clark-Brown dcb@havahtx.com

The ABTA has invested more than $36 million in over 800 research projects, leading the charge in advancing progress and fostering hope for life-changing treatments and care for brain tumor patients. CHICAGO, Oct. 22, 2024 /PRNewswire/ -- The American Brain Tumor Association (ABTA) is proud to announce its ongoing commitment to brain tumor research with the funding of 24 new research projects. For more than 50 years, the ABTA has remained committed to funding brain tumor research, especially for early-stage investigators. This investment, which starts with the earliest phase of medical training, seeks to not only drive brain tumor research forward, but empower the next generation of physicians and scientists to propel the neuro-oncology field forward. "Through the funding of brain tumor research, the ABTA empowers talented researchers to pursue challenging questions in neuro-oncology," says Ralph DeVitto, ABTA president and chief executive officer. "We are proud to continue our legacy of funding critical brain tumor research and bringing hope to patients." This year's slate of awarded grants includes research projects that span several areas of brain tumor research, including biomarkers, epigenetics, experimental therapeutics, immunotherapy, and invasion for adult and pediatric brain tumors. The ABTA extends its congratulations to the 2024 grant recipients listed below. To learn more about current ABTA grant recipients, visit abta.org/research/research-funding-impact-2. Research Collaboration Grants are two-year, $200,000 grants awarded for multi-investigator multidisciplinary brain tumor collaborative research projects. Grant awardees include: Jacques Lux, PhD–University of Texas Southwestern Medical Center, with Co-PI Wen Jiang, MD, PhD–University of Texas M.D. Anderson Cancer Center Pavithra Viswanath, PhD–University of California, San Francisco, with Co-PI, Peng Zhang, PhD–Northwestern University Basic Research Fellowships are two-year, $100,000 mentored grants awarded to post-doctoral fellows to retain talented researchers in the neuro-oncology field. Fellowship awardees include: Adam Grippin, MD, PhD–University of Texas M.D. Anderson Cancer Center Mark Youngblood, MD, PhD–Northwestern University Discovery Grants are one-year, $50,000 grants supporting innovative, bold, high-impact approaches with the potential to transform current diagnostic or treatment standards of care. Grant awardees include: Toshiro Hara, PhD–University of Michigan Tanner Johanns, MD, PhD–Washington University in St. Louis Julie Miller, MD, PhD–Massachusetts General Hospital Chrystian Junqueira Alves, PhD–Icahn School of Medicine at Mount Sinai Gilbert Rahme, PhD–State University of New York at Stony Brook David Raleigh, MD, PhD–University of California, San Francisco Artak Tovmasyan, PhD–Dignity Health/St. Joseph's Hospital & Medical Center Dionysios Watson, MD, PhD–Sylvester Comprehensive Cancer Center/University of Miami Peng Zhang, PhD–Northwestern University Medical Student Summer Fellowships are three-month, $3,000 grants awarded to medical students to conduct brain tumor research projects under the mentorship of neuro-oncology experts. Fellows include: Lucy Chen, AB–Johns Hopkins University School of Medicine Harrsha Congivaram, BS–Northwestern University Feinberg School of Medicine Karenna Groff, MEng–New York University Grossman School of Medicine Joseph Inger, BS–Brown University Jill Jones, BS–Boston Children's Hospital Seth Meade, BSE–Cleveland Clinic Jonathon Mitchell, BS–Miller School of Medicine of the University of Miami Megan Parker, BS–Johns Hopkins University School of Medicine Jorge Salcedo, AB, AB–University of California, Los Angeles Ethan Schonfeld, MS–Stanford University Suchet Taori, BA–University of Pittsburgh Awarding of these grants would not be possible without the incredible support of our donors and our partner organizations including the Joel A. Gingras Memorial Foundation, Southeastern Brain Tumor Foundation, BrainUp, Tap Cancer Out, and Gladiator Project. The ABTA will soon begin accepting applications for its 2025 Discovery Grants, Basic Research Fellowships, and Jack and Fay Netchin Medical Student Summer Fellowships. In addition, ABTA partnered grants, the CNS Metastasis Research Grant and Brain Tumor Funders' Collaborative grant, will begin accepting applications soon. For more information on grant opportunities and deadlines, visit abta.org/grants. About the ABTA Founded in 1973, the American Brain Tumor Association provides comprehensive resources to support the complex needs of brain tumor patients and caregivers, across all ages and tumor types, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnoses, treatments, and care. To learn more, visit abta.org or call 800-886-ABTA (2282). SOURCE American Brain Tumor Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Results Presented in an Oral Presentation at the Society for Neuroscience Annual Meeting RNS60 Protected Motor Neurons and Neuromuscular Junctions and Reduced Neuroinflammation TACOMA, Wash., Oct. 9, 2024 /PRNewswire/ -- Revalesio, a clinical-stage pharmaceutical company developing treatments for acute and chronic neurological disorders, today announced new data showing that Revalesio's investigational therapeutic, RNS60, protected motor neurons in the prpTDP-43A315T-UeGFP mouse model of ALS. PrpTDP-43A315T-UeGFP mice express a mutation of the human TDP43 gene and develop progressive motor neuron degeneration, leading to gait abnormalities, muscle weakness, and eventually death, mimicking key features of ALS. TDP43-associated pathology is found in approximately 97% of people with ALS. The results were presented today during the Nanosymposium ALS Therapeutics at the Society for Neuroscience Annual Meeting. "There is a great need for treatment options to slow the progression of ALS," said Hande Ozdinler, Ph.D., Associate Professor of Neurology at Northwestern University Feinberg School of Medicine and Principal Investigator of the study. "These promising preclinical findings warrant further investigation of the potential role of RNS60 in protecting motor neurons and preserving mitochondrial function, key factors in the pathogenesis of ALS." "These exciting results suggest that RNS60 has potential to mitigate neurodegeneration due to TDP-43 pathology," said Mukesh Gautam, PhD, Research Assistant Professor of Neurology at Northwestern University Feinberg School of Medicine and presenting author at the Society for Neuroscience Annual Meeting. "Since TDP-43 pathology contributes to a large population of both familial and sporadic ALS patients, these results are particularly promising." In this study, 30-day old prpTDP-43A315T-UeGFP mice showing signs of degeneration were treated with RNS60 every other day for 60 days. Immunohistochemistry was performed to quantitatively assess activated microglia (immune cells that patrol the central nervous system [CNS] for pathogens and damage) and activated astrocytes (cells in the CNS that perform metabolic, structural, homeostatic, and neuroprotective tasks). Ultrastructural integrity of neuronal mitochondria was studied via electron microscopy. RNS60 treatment significantly a) improved mitochondrial ultrastructure in the motor neurons, b) reduced the extent of astrogliosis and microgliosis in mice and c) protected health and stability of upper motor neurons and neuromuscular junctions compared to placebo-treated mice. "These results add to the growing body of preclinical and clinical evidence that RNS60 may provide neuroprotective effects in ALS," said Bert van den Bergh, Revalesio's Executive Chairman on the Board of Directors, and former President of Neuroscience Products at Eli Lilly and Company. "We are simultaneously advancing RNS60 in planned clinical trials for the treatment of patients with ALS and ischemic stroke with the goal of improving the lives of people with these devastating conditions." About RNS60 RNS60 is an investigational therapeutic being developed to provide disease modifying and potentially restorative treatments for neurological diseases. In preclinical studies, RNS60 activated intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protected neurons and oligodendrocytes and modulated the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.S. Food and Drug Administration. About Revalesio Revalesio is a clinical-stage pharmaceutical company with a vision to change the future of treatment for acute and chronic neurological disorders. The company's lead clinical program for RNS60 is ischemic stroke with additional programs in ALS and other neurological disorders. The company's pioneering technology, founded in physics, addresses fundamental mechanisms involved with proper cellular function to slow disease progression and improve quality of life. For more information, please visit revalesio.com and engage with us on LinkedIn. Media Lori Murray [email protected] SOURCE Revalesio Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED